---
title: "Global Intravenous (IV) Therapy and Vein Access Market Report 2025 - Market Size, Share, Price, Trend and Forecast"
datePublished: Fri Oct 31 2025 19:00:53 GMT+0000 (Coordinated Universal Time)
cuid: cmhf7y5d0000502ju8khi2742
slug: global-intravenous-iv-therapy-and-vein-access-market-report-2025-market-size-share-price-trend-and-forecast

---

# Global Intravenous (IV) Therapy and Vein Access Market Report 2025 - Market Size, Share, Price, Trend and Forecast

<p><strong>MARKET INSIGHTS</strong></p><p>
</p><p>Global Intravenous (IV) Therapy and Vein Access market size was valued at USD 18.7 billion in 2024. The market is projected to grow from USD 20.1 billion in 2025 to USD 34.9 billion by 2032, exhibiting a CAGR of 7.2% during the forecast period.</p><div><b>Download FREE Sample of this Report @ 
            <a href="https://www.24chemicalresearch.com/download-sample/175701/global-intravenous-therapy-vein-access-market">
            https://www.24chemicalresearch.com/download-sample/175701/global-intravenous-therapy-vein-access-market</a></b></div><br><p>
</p><p>Intravenous therapy and vein access products are medical devices designed to deliver fluids, medications, and nutrients directly into the bloodstream. These solutions encompass infusion pumps, catheters, implantable ports, and specialized needles that enable efficient vascular access for therapeutic interventions. The technology plays a critical role in hospital settings, emergency care, and chronic disease management where rapid medication delivery or continuous fluid administration is required.</p><p>
</p><p>The market growth is driven by increasing surgical procedures, rising prevalence of chronic diseases requiring long-term IV therapy, and technological advancements in catheter materials. The aging population requiring frequent medical interventions further accelerates demand, with North America currently holding the largest market share due to advanced healthcare infrastructure. Key players like Becton Dickinson, Baxter International, and Fresenius Kabi continue to innovate with safety-engineered products to reduce needlestick injuries and bloodstream infections.</p><p>
<strong>MARKET DYNAMICS</strong></p><p>
<strong>MARKET DRIVERS</strong></p><p>
</p><p style="text-align:center"><strong>Rising Prevalence of Chronic Diseases to Accelerate Market Growth</strong></p><p>
</p><p>The global intravenous therapy and vein access market is witnessing substantial growth due to the increasing prevalence of chronic diseases requiring long-term treatment. Conditions such as cancer, diabetes, and cardiovascular diseases often necessitate frequent intravenous drug administration and nutritional support. The World Health Organization estimates that chronic diseases account for approximately 74% of all deaths globally, creating sustained demand for IV therapy solutions. Furthermore, the aging population, which is more susceptible to chronic conditions, is expanding rapidly. For instance, the population aged 65+ is projected to double by 2050 across developed nations, further driving market expansion.</p><p>
</p><p style="text-align:center"><strong>Technological Advancements in Vascular Access Devices to Fuel Adoption</strong></p><p>
</p><p>Continuous innovation in vascular access technology is significantly contributing to market growth. Recent developments include antimicrobial catheter coatings that reduce infection risks, ultrasound-guided insertion systems improving first-stick success rates, and smart IV pumps with dose-error reduction software. These advancements enhance patient safety and treatment efficacy while reducing healthcare costs associated with complications. For example, modern midline catheters now offer dwell times extending beyond 30 days, minimizing the need for frequent reinsertions. Such technological improvements are driving wider adoption across both hospital and home care settings.</p><p>
</p><p style="text-align:center"><strong>Growing Preference for Home Infusion Therapy to Expand Market Reach</strong></p><p>
</p><p>The shift toward home healthcare services is creating new growth opportunities for IV therapy providers. Home infusion therapy offers cost savings (typically 30-50% lower than hospital treatment) while improving patient comfort and satisfaction. This trend accelerated during the pandemic and continues gaining momentum, with specialty medications for conditions like autoimmune disorders and infections increasingly administered at home. Payers are supporting this transition through favorable reimbursement policies, recognizing both the clinical benefits and economic advantages of home-based IV care.</p><p>
<strong>MARKET RESTRAINTS</strong></p><p>
</p><p style="text-align:center"><strong>High Risk of Catheter-Related Complications to Limit Market Expansion</strong></p><p>
</p><p>Despite market growth potential, catheter-related bloodstream infections (CRBSIs) remain a significant restraint. These complications occur in approximately 3-5% of central line insertions and can increase hospital stays by 7-21 days while adding substantial treatment costs. Peripheral IV failures are even more common, with studies showing failure rates reaching 46% within the first 24 hours of insertion. Such complications not only impact patient outcomes but also contribute to healthcare system inefficiencies, causing some providers to reconsider IV therapy options in favor of alternative administration routes when possible.</p><p>
</p><p style="text-align:center"><strong>Stringent Regulatory Requirements to Slow Product Approvals</strong></p><p>
</p><p>The IV therapy market faces rigorous regulatory scrutiny due to the high-risk nature of vascular access devices. Regulatory bodies require extensive clinical data demonstrating safety and efficacy before granting approvals, which can delay product launches by several years. Recent changes to medical device classification systems have further complicated the approval process for some IV products. While these measures protect patient safety, they create barriers to market entry that can stifle innovation and limit competition, particularly for smaller manufacturers with constrained resources.</p><p>
</p><p style="text-align:center"><strong>Nursing Shortages to Impact Service Delivery Capabilities</strong></p><p>
</p><p>Growing global nursing shortages present operational challenges for IV therapy services. Specialized vascular access teams require extensive training, and the current shortfall of qualified nurses (projected to reach 13 million by 2030) makes staffing these teams increasingly difficult. This shortage leads to delayed procedures, increased workload for existing staff, and potential compromises in care quality during peak demand periods. The situation is particularly acute in rural areas, where healthcare providers struggle to maintain adequate IV therapy services for their patient populations.</p><p>
<strong>MARKET OPPORTUNITIES</strong></p><p>
</p><p style="text-align:center"><strong>Expansion in Emerging Markets to Create New Growth Avenues</strong></p><p>
</p><p>Developing economies present significant untapped potential for IV therapy market expansion. Improving healthcare infrastructure and increasing treatment accessibility in Asia-Pacific and Latin American countries are creating new opportunities. Governments in these regions are investing heavily in hospital development and modernizing clinical practices, with the Asian IV therapy market projected to grow at over 8% CAGR through 2032. Market leaders can capitalize on this growth by establishing local manufacturing facilities, forging partnerships with regional distributors, and adapting products to meet specific market needs while maintaining competitive pricing.</p><p>
</p><p style="text-align:center"><strong>Development of Biologic Therapies to Drive Demand for Advanced Delivery Systems</strong></p><p>
</p><p>The rapid development of biologic drugs and cell therapies is creating demand for specialized IV delivery systems. Many next-generation therapies require precise infusion rates, temperature control, and compatibility with unique formulations. Market players investing in development of advanced catheters, smart pumps, and monitoring systems tailored for biologic administration stand to gain significant competitive advantages. The global biologics market is expected to reach $650 billion by 2030, representing a substantial adjacent opportunity for IV therapy solution providers.</p><p>
</p><p style="text-align:center"><strong>Integration of Digital Health Technologies to Transform IV Therapy</strong></p><p>
</p><p>Emerging digital health technologies are creating opportunities to enhance IV therapy administration and monitoring. Remote patient monitoring systems can track infusion progress and detect complications in real-time, while predictive analytics can optimize catheter selection and placement. Artificial intelligence applications are being developed to improve vein detection and insertion success rates, particularly for difficult-access patients. These digital innovations not only improve clinical outcomes but also create opportunities for value-added service models and long-term patient engagement strategies.</p><p>
<strong>MARKET CHALLENGES</strong></p><p>
</p><p style="text-align:center"><strong>Cost Pressure from Healthcare Budget Constraints to Impact Margins</strong></p><p>
</p><p>Ongoing healthcare cost containment efforts worldwide are putting significant pricing pressure on IV therapy products and services. Payers are implementing stricter procurement processes and demanding greater value demonstration, forcing manufacturers to balance innovation with cost considerations. Group purchasing organizations now account for over 70% of hospital supply purchases in some markets, intensifying competition and margin compression. Manufacturers must optimize production efficiencies and demonstrate clear cost-benefit advantages to maintain profitability in this challenging environment.</p><p>
</p><p><strong>Other Challenges</strong></p><p>
</p><p><strong>Supply Chain Vulnerabilities</strong></p><p>
The IV therapy market remains susceptible to supply chain disruptions, as evidenced during the COVID-19 pandemic. Critical components like specialized plastics and electronic components for smart pumps face periodic shortages. These disruptions can delay product availability and increase costs, particularly for single-use disposable items that constitute the bulk of IV therapy consumables.</p><p>
</p><p><strong>Reimbursement Complexity</strong></p><p>
Varied reimbursement policies across regions create administrative burdens for providers and can limit patient access to advanced IV therapies. The lack of standardized coding for newer vascular access devices and procedures often delays payment cycles and creates financial uncertainty for healthcare facilities implementing innovative solutions.</p><p>

<strong>Segment Analysis:</strong>
</p><p>
				<strong>Other</strong>
			
			
				<strong>Intravenous Catheters</strong> hold the largest share owing to their essential role in direct vein access and fluid delivery.
			
		
		
			By Application
			
				</p><p>
<strong>Key Industry Players</strong></p><p>
</p><p style="text-align:center"><strong>Companies Strive to Strengthen their Product Portfolio to Sustain Competition</strong></p><p>
</p><p>The competitive landscape of the global Intravenous (IV) Therapy and Vein Access market is semi-consolidated, featuring a mix of large multinational corporations, mid-sized innovators, and smaller specialized firms. This structure fosters innovation while allowing established players to dominate through scale and distribution networks. <strong>B. Braun Melsungen AG</strong> stands out as a leading player, driven by its comprehensive product portfolio that includes advanced IV catheters, infusion pumps, and vein access devices, coupled with a robust global presence spanning North America, Europe, Asia-Pacific, and emerging markets. The company's focus on safety-engineered products has helped it capture a substantial market share, particularly in hospital settings where reliability is paramount.</p><p>
</p><p><strong>Becton, Dickinson and Company (BD)</strong> and <strong>Baxter International Inc.</strong> also commanded significant portions of the market in 2024, with BD leading in vein access technologies like safety needles and catheters, while Baxter excels in infusion therapy solutions. Their growth stems from innovative portfolios tailored to rising demands in chronic disease management and surgical procedures, bolstered by strong footholds in research-driven end-markets such as oncology and critical care. Furthermore, these firms have benefited from regulatory approvals for next-generation devices that minimize infection risks, a critical factor in IV therapy adoption.</p><p>
</p><p>Looking ahead, the growth initiatives of key playersâincluding strategic geographical expansions into high-growth regions like Asia-Pacific and Latin America, alongside frequent new product launchesâare poised to significantly expand their market shares through the forecast period to 2032. For instance, investments in smart infusion systems integrated with digital health platforms are addressing the need for precise drug delivery in outpatient settings. However, challenges like supply chain disruptions and stringent reimbursement policies in various countries could temper short-term gains, prompting companies to diversify manufacturing bases.</p><p>
</p><p>Meanwhile, <strong>Fresenius Kabi AG</strong> and <strong>ICU Medical, Inc.</strong> are actively fortifying their positions through hefty R&amp;D investments exceeding hundreds of millions annually, forging strategic partnerships with healthcare providers, and pursuing acquisitions to broaden their offerings in implantable ports and hypodermic needles. These efforts not only enhance product innovation but also ensure resilience against competitive pressures. In a market projected to grow steadily due to aging populations and increasing surgical volumes, such proactive strategies will likely sustain long-term leadership. Overall, the interplay between innovation, compliance, and market access defines the competitive dynamics, with leaders adapting to evolving clinical needs while smaller players niche down into specialized vein access solutions.</p><p>
</p><p>The sector's emphasis on patient safety and efficiency continues to drive mergers and collaborations, as seen in recent consolidations that combine expertise in IV therapy with advanced vein access technologies. This consolidation trend, while intensifying competition, ultimately benefits end-users through improved product quality and accessibility. As healthcare systems worldwide prioritize minimally invasive procedures, companies that balance cost-effectiveness with technological superiority will thrive, shaping a more integrated market landscape by 2032.</p><p>
<strong>List of Key Intravenous (IV) Therapy and Vein Access Companies Profiled</strong></p><p>
</p><p>B. Braun Melsungen AG (Germany)</p><p>Baxter International Inc. (U.S.)</p><p>Becton, Dickinson and Company (U.S.)</p><p>C. R. Bard, Inc. (U.S.)</p><p>Fresenius Kabi AG (Germany)</p><p>ICU Medical, Inc. (U.S.)</p><p>Terumo Corporation (Japan)</p><p>Smiths Medical (U.S.)</p><p>AngioDynamics, Inc. (U.S.)</p><p>
<strong>Advancements in Safety-Engineered Devices to Emerge as a Trend in the Market</strong></p><p>
</p><p>Advancements in safety-engineered vein access devices, particularly the development of needleless connectors and retractable needle IV catheters, have transformed intravenous therapy practices by significantly reducing the risk of needlestick injuries and bloodstream infections. These innovations address longstanding challenges in patient safety, with recent designs incorporating antimicrobial coatings and passive safety mechanisms that activate automatically upon needle withdrawal. Furthermore, the integration of smart technologies, such as RFID tracking for device monitoring, has enhanced workflow efficiency in healthcare settings. This trend is driven by stringent regulatory requirements worldwide, leading to a notable increase in adoption rates. For instance, the global market for IV therapy and vein access devices was valued at approximately $5.8 billion in 2024, reflecting robust growth fueled by these technological improvements.</p><p>
<strong>Other Trends</strong></p><p>
</p><p><strong>Rising Prevalence of Chronic Diseases</strong></p><p>
</p><p>The escalating incidence of chronic conditions like cancer, diabetes, and cardiovascular diseases has intensified the need for reliable IV therapy solutions, propelling market expansion. Patients with these ailments often require prolonged vascular access for chemotherapy, hydration, or nutritional support, which underscores the demand for durable and minimally invasive devices such as peripherally inserted central catheters (PICCs) and midline catheters. While hospital admissions for acute care remain high, the shift toward managing chronic illnesses in outpatient settings has further amplified this trend, as healthcare providers seek devices that minimize complications like phlebitis or thrombosis.</p><p>
</p><p><strong>Growth in Home Healthcare Services</strong></p><p>
</p><p>Parallel to this, the burgeoning home healthcare sector is reshaping IV therapy delivery, allowing patients to receive treatments outside traditional clinical environments. This evolution is supported by portable infusion pumps and user-friendly vein access kits, which empower caregivers and reduce healthcare costs. However, challenges such as ensuring sterile techniques at home persist, prompting ongoing innovations in training protocols and device ergonomics to maintain safety standards.</p><p>
<strong>Expansion in Ambulatory and Infusion Centers</strong></p><p>
</p><p>The proliferation of ambulatory surgery centers and specialized infusion clinics is accelerating the utilization of advanced IV and vein access products. Increased R&amp;D investments in biocompatible materials and ultrasound-guided insertion techniques are yielding more precise and less traumatic access methods, applicable across diverse therapeutic areas including antibiotic administration and pain management. New product launches, such as next-generation central venous catheters with antimicrobial barriers, alongside collaborative efforts between device manufacturers and healthcare networks, are bolstering these developments. As a result, the market is poised for sustained growth, projected to reach $10.2 billion by 2032, expanding at a compound annual growth rate (CAGR) of 7.3% from 2025 onward, driven by these dynamic shifts in care delivery models.</p><p>


  
    North America
    
      North America stands as the dominant global market for Intravenous (IV) Therapy and Vein Access, primarily driven by the United States. This region's leadership is anchored in its advanced healthcare infrastructure, high healthcare expenditure, and strong emphasis on patient safety and infection control protocols. The region benefits from the presence of major global market players like Becton Dickinson and Baxter International, which drive innovation in product development and distribution networks. A highly developed regulatory framework, particularly from the U.S. Food and Drug Administration (FDA), ensures stringent product quality and safety standards, fostering trust and widespread adoption. High procedural volumes in hospitals and specialized clinics for chronic disease management, fluid resuscitation, and chemotherapy further solidify its market position.
    
  
  
  
    
      Market Drivers &amp; Technological Leadership</p><p>
      The region's dominance is fueled by early adoption of advanced technologies like smart infusion pumps and safety-engineered catheters. A culture of rapid innovation and significant R&amp;D investments by key industry players continuously elevates the standard of care, focusing on reducing needlestick injuries and healthcare-associated infections.
    
    
      Regulatory Environment &amp; Reimbursement</p><p>
      Stringent regulations from the FDA and other bodies mandate the use of safety devices, creating a consistent demand. Favorable reimbursement policies for IV therapies and vein access procedures within the U.S. healthcare system further support market growth and accessibility for patients.
    
    
      Competitive Landscape</p><p>
      The market is characterized by intense competition among well-established multinational corporations. This competition drives continuous product portfolio expansion, strategic mergers and acquisitions, and a focus on developing integrated solutions for hospitals and outpatient centers.
    
    
      Healthcare Ecosystem &amp; End-User Demand</p><p>
      A high concentration of advanced hospitals, ambulatory surgical centers, and home care services creates sustained demand. The growing prevalence of chronic diseases requiring long-term IV therapy and an aging population needing frequent venous access are key factors underpinning the robust market.
    
  
</p><p>
</p><p><strong>Europe</strong></p><p>
Europe represents a mature and highly regulated market for IV therapy and vein access products. The region's growth is supported by universal healthcare systems in many countries, ensuring broad access to medical procedures. The European market is characterized by a strong focus on cost-containment and procurement efficiency, which influences purchasing decisions by hospital groups. The presence of manufacturers like B. Braun and Fresenius Kabi provides a strong local manufacturing base. The regulatory oversight from the European Medicines Agency (EMA) and the implementation of the Medical Device Regulation (MDR) ensure high standards for product safety and performance, similar to North America.</p><p>
</p><p><strong>Asia-Pacific</strong></p><p>
The Asia-Pacific region is identified as the fastest-growing market for IV therapy and vein access, driven by rapidly improving healthcare infrastructure, increasing healthcare expenditure, and a growing patient population. Countries like China, Japan, and India are key contributors. Market expansion is fueled by rising medical tourism, increasing surgical volumes, and greater awareness of infection control practices. Local manufacturers are expanding their presence, but the market also sees significant import activity. The regulatory landscapes are evolving, with countries strengthening their approval processes to ensure product quality and safety.</p><p>
</p><p><strong>South America</strong></p><p>
The South American market for IV therapy and vein access is developing, with growth influenced by economic conditions and ongoing healthcare reforms. Brazil is the largest market in the region. Growth is driven by efforts to expand healthcare coverage and improve hospital infrastructure. The market faces challenges related to economic volatility and varying regulatory standards across different countries, which can impact the pace of adoption for advanced medical devices.</p><p>
</p><p><strong>Middle East &amp; Africa</strong></p><p>
The MEA region shows varied market dynamics. The Gulf Cooperation Council (GCC) countries, with their high per capita healthcare spending and modern medical facilities, represent the more advanced segment of the market. The broader region's growth is propelled by government initiatives to enhance healthcare services and infrastructure. However, market penetration can be uneven, with accessibility and affordability remaining key challenges in some African nations.</p><p>


<strong>Report Scope</strong></p><p>
</p><p>This report presents a comprehensive analysis of the global and regional markets for Intravenous (IV) Therapy and Vein Access, covering the period from 2022 to 2028. It includes detailed insights into the current market status and outlook across various regions and countries, with specific focus on:</p><p>
</p><p><strong>Sales, sales volume, and revenue forecasts</strong></p><p><strong>Detailed segmentation by type and application</strong></p><p>
</p><p>In addition, the report offers in-depth profiles of key industry players, including:</p><p>
</p><p>Company profiles</p><p>Product specifications</p><p>Production capacity and sales</p><p>Revenue, pricing, gross margins</p><p>Sales performance</p><p>
</p><p>It further examines the competitive landscape, highlighting the major vendors and identifying the critical factors expected to challenge market growth.</p><p>
</p><p>As part of this research, we surveyed Intravenous (IV) Therapy and Vein Access companies and industry experts. The survey covered various aspects, including:</p><p>
</p><p>Revenue and demand trends</p><p>Product types and recent developments</p><p>Strategic plans and market drivers</p><p>Industry challenges, obstacles, and potential risks</p><p>
<strong>FREQUENTLY ASKED QUESTIONS:</strong></p><p>
<strong>What is the current market size of Global Intravenous (IV) Therapy and Vein Access Market?</strong></p><p>
</p><p><strong>-&gt;</strong> The Global Intravenous (IV) Therapy and Vein Access Market was valued at <strong>USD 20.1 billion in 2025</strong> and is expected to reach <strong>USD 34.9 billion by 2032</strong>.</p><p>
<strong>Which key companies operate in Global Intravenous (IV) Therapy and Vein Access Market?</strong></p><p>
</p><p><strong>-&gt; Key players</strong> include <strong>B. Braun, Baxter International, Becton Dickinson, C. R. Bard, Fresenius Kabi, and Hospira(ICU Medical)</strong>, among others.</p><p>
<strong>What are the key growth drivers of Global Intravenous (IV) Therapy and Vein Access Market?</strong></p><p>
</p><p>-&gt; Key growth drivers include <strong>increasing surgical procedures, rising prevalence of chronic diseases requiring long-term IV therapy, and technological advancements in catheter materials</strong>.</p><p>
<strong>Which region dominates the market?</strong></p><p>
</p><p><strong>-&gt; North America</strong> is the dominant region, while <strong>Asia-Pacific</strong> shows significant growth potential.</p><p>
<strong>What are the emerging trends?</strong></p><p>
</p><p>-&gt; Emerging trends include <strong>safety-engineered products to reduce needlestick injuries and bloodstream infections</strong>.</p><p>

</p>

<div><b>Get the Complete Report & TOC @ 
            <a href="https://www.24chemicalresearch.com/reports/175701/global-intravenous-therapy-vein-access-market">
            https://www.24chemicalresearch.com/reports/175701/global-intravenous-therapy-vein-access-market</a></b></div><br>
            <b>Table of Content:</b><p>Table of Content<br />
<br />
Chapter 1 Executive Summary<br />
<br />
Chapter 2 Abbreviation and Acronyms<br />
<br />
Chapter 3 Preface<br />
3.1 Research Scope<br />
3.2 Research Methodology<br />
  3.2.1 Primary Sources<br />
  3.2.2 Secondary Sources<br />
  3.2.3 Assumptions<br />
		<br />
Chapter 4 Market Landscape<br />
4.1 Market Overview<br />
4.2 Classification/Types<br />
4.3 Application/End Users<br />
<br />
Chapter 5 Market Trend Analysis <br />
5.1 Introduction<br />
5.2 Drivers<br />
5.3 Restraints<br />
5.4 Opportunities<br />
5.5 Threats<br />
<br />
Chapter 6 Industry Chain Analysis<br />
6.1 Upstream/Suppliers Analysis<br />
6.2 Intravenous (IV) Therapy and Vein Access Analysis<br />
  6.2.1 Technology Analysis<br />
  6.2.2 Cost Analysis<br />
  6.2.3 Market Channel Analysis<br />
6.3 Downstream Buyers/End Users<br />
<br />
Chapter 7 Latest Market Dynamics<br />
7.1 Latest News<br />
7.2 Merger and Acquisition<br />
7.3 Planned/Future Project<br />
7.4 Policy Dynamics<br />
<br />
Chapter 8 Trading Analysis<br />
8.1 Export of Intravenous (IV) Therapy and Vein Access by Region<br />
8.2 Import of Intravenous (IV) Therapy and Vein Access by Region<br />
8.3 Balance of Trade<br />
<br />
Chapter 9 Historical and Current Intravenous (IV) Therapy and Vein Access in North America (2017-2021)<br />
9.1 Intravenous (IV) Therapy and Vein Access Supply <br />
9.2 Intravenous (IV) Therapy and Vein Access Demand by End Use<br />
9.3 Competition by Players/Suppliers<br />
9.4 Type Segmentation and Price<br />
9.5 Key Countries Analysis<br />
  9.5.1 US<br />
  9.5.2 Canada<br />
  9.5.3 Mexico<br />
<br />
Chapter 10 Historical and Current Intravenous (IV) Therapy and Vein Access in South America (2017-2021)<br />
10.1 Intravenous (IV) Therapy and Vein Access Supply <br />
10.2 Intravenous (IV)</p>

<div><b>Get the Complete Report & TOC @ 
            <a href="https://www.24chemicalresearch.com/reports/175701/global-intravenous-therapy-vein-access-market">
            https://www.24chemicalresearch.com/reports/175701/global-intravenous-therapy-vein-access-market</a></b></div><br>

<b>CONTACT US:</b><br>
            203A, City Vista, Fountain Road, Kharadi, Pune, India - 411014<br>
            International: +1(332) 2424 294<br>
            Asia: +91 9169162030 <br><br>
            Follow Us On LinkedIn: <a href="https://www.linkedin.com/company/24chemicalresearch/">24ChemicalResearch LinkedIn</a>